TLC Reports Second Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan- August 12, 2021 - TLC, a. | August 13, 2021
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan - May 26, 2021 - TLC (Nasdaq: TLC, TWO: 4152), a clinical-stagespecialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of Zydus Cadila group (Zydus) (NSE: CADILAHC), an innovative, global pharmaceutical group that discovers, develops, manufactures and markets a broad range of healthcare therapies, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC™ on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC™ in India.